Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases Read more
INMARK results suggest prompt treatment of IPF with antifibrotics to slow disease progression Read more
Astellas and Frequency Therapeutics Enter into License Agreement for FX-322, a Regenerative Treatment Candidate for Hearing Loss Read more
TraceLink Partners With Excellis to Provide Local Implementation Services for its Russia Compliance Solution Through One Global Compliance Platform Read more
Inflection Biosciences and AUM Biosciences Announce Global License Agreement for PIM/PI3K/mTOR Inhibitors Read more
Amgen And Allergan’s MVASI (bevacizumab-awwb) And KANJINTI (trastuzumab-anns) Now Available In The United States Read more
FDA approves new treatment for complicated urinary tract and complicated intra-abdominal infections Read more